The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online
doi:10.1084/jem.20070763
The Journal of Experimental Medicine, Vol. 205, No. 2, 315-322
The Rockefeller University Press, 0022-1007 $30.00
© Guiducci et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1954K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guiducci, C.
Right arrow Articles by Soumelis, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guiducci, C.
Right arrow Articles by Soumelis, V.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

BRIEF DEFINITIVE REPORT

 PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation

Cristiana Guiducci1, Cristina Ghirelli2,3, Marie-Annick Marloie-Provost2, Tracy Matray1, Robert L. Coffman1, Yong-Jun Liu4, Franck J. Barrat1, and Vassili Soumelis2,3

1 Dynavax Technologies Corporation, Berkeley, CA 94710
2 Department of Immunology, Institut Curie, 75005 Paris, France
3 Institut National de la Santé et de la Recherche Médicale, U653, 75005 Paris, France
4 Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030

CORRESPONDENCE Franck J. Barrat: fbarrat{at}dynavax.com OR Vassili Soumelis: vassili.soumelis{at}curie.net

Plasmacytoid predendritic cells (pDCs) are the main producers of type I interferon (IFN) in response to Toll-like receptor (TLR) stimulation. Phosphatidylinositol-3 kinase (PI3K) has been shown to be activated by TLR triggering in multiple cell types; however, its role in pDC function is not known. We show that PI3K is activated by TLR stimulation in primary human pDCs and demonstrate, using specific inhibitors, that PI3K is required for type I IFN production by pDCs, both at the transcriptional and protein levels. Importantly, PI3K was not involved in other proinflammatory responses of pDCs, including tumor necrosis factor {alpha} and interleukin 6 production and DC differentiation. pDCs preferentially expressed the PI3K {delta} subunit, which was specifically involved in the control of type I IFN production. Although uptake and endosomal trafficking of TLR ligands were not affected in the presence of PI3K inhibitors, there was a dramatic defect in the nuclear translocation of IFN regulatory factor (IRF) 7, whereas nuclear factor {kappa}B activation was preserved. Thus, PI3K selectively controls type I IFN production by regulating IRF-7 nuclear translocation in human pDCs and could serve as a novel target to inhibit pathogenic type I IFN in autoimmune diseases.

F.J. Barrat and V. Soumelis contributed equally to this work.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS